论文部分内容阅读
目的:探讨分析前列腺癌患者89Sr治疗后机体免疫功能的变化及其临床意义。方法:87例前列腺癌患者经89Srcl2治疗1月,采用流式细胞术检测治疗前后其外周血淋巴细胞亚群,速率散射免疫比浊分析法检测其免疫球蛋白的含量。结果:经89Sr治疗后,患者CD3、CD19、CD4比例均明显升高,CD8比例明显降低,差异均有统计学意义(P<0.05),而CD16+CD56+无明显变化;IgG和IgA明显升高,差异均有统计学意义(P<0.05),而IgM无明显变化。结论:用89Srcl2治疗前列腺癌可以有效提高患者的免疫水平,可通过监测机体免疫功能指标的变化89Sr核素的疗效。
Objective: To investigate the changes of the immune function of 89Sr patients after prostate cancer and its clinical significance. Methods: Eighty-seven prostate cancer patients were treated with 89Srcl2 for 1 month. The peripheral blood lymphocyte subsets were detected by flow cytometry before and after treatment. The immunoglobulin contents were determined by rate-scattering immunoturbidimetric assay. Results: After treatment with 89Sr, the proportion of CD3, CD19 and CD4 were significantly increased, while the proportion of CD8 was significantly decreased (P <0.05), while there was no significant change in CD16 + CD56 + and IgG and IgA , The differences were statistically significant (P <0.05), while no significant change in IgM. Conclusion: 89Srcl2 treatment of prostate cancer patients can effectively improve the immune level, by monitoring the body’s immune function changes 89Sr nuclide efficacy.